• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by Voyager Acquisition Corp

    8/6/25 5:17:58 PM ET
    $VACH
    Get the next $VACH alert in real time by email
    RW 1 voyageracq_rw.htm RW

     

    August 6, 2025

     

    VIA EDGAR

     

    U.S. Securities and Exchange Commission

    Division of Corporation Finance

    Office of Life Sciences

    100 F Street NE

    Washington, D.C. 20549

     

    Attn: Tyler Howes

     

    Re: Voyager Acquisition Corp
      Request to Withdraw Registration Statement on Form F-4
      Filed July 17, 2025
      File No. 333-288719

     

    Ladies and Gentlemen:

     

    Voyager Acquisition Corp (the “Company”) respectfully requests, pursuant to Rule 477(a) under the Securities Act of 1933, as amended (the “Act”), the immediate withdrawal of its Registration Statement on Form F-4 (File No. 333-288719), initially filed with the Securities and Exchange Commission (the “Commission”) on July 17, 2025, together with all exhibits and amendments thereto (collectively, the “Registration Statement”). The Registration Statement has not been declared effective and no securities of the Company were sold in connection with the offering.

     

    The Company also requests that, in accordance with Rule 457(p) of the Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use by the Company, registrant or co-registrants to the Registration Statement.

     

    If you have any questions or require further information regarding this application for withdrawal, please do not hesitate to contact Michael J. Blankenship at (713) 651-2678.

     

    Very truly yours,
     
    /s/ Adeel Rouf
     
    Adeel Rouf
    Chief Executive Office
    Voyager Acquisition Corp

     

     

     

    Get the next $VACH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VACH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VACH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VERAXA Biotech and Voyager Acquisition Corp. Announce Filing of Form F-4 Registration Statement with the SEC

    ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG ("VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp.,  a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ:VACH, "Voyager" or the "SPAC")), announced today the filing of a registration statement on Form F-4 (the "Registration Statement"), which includes a preliminary proxy statement, with the U.S. Securities and Exchange Commission ("SEC") in regards to the proposed Business Combination Agreement announced April 23, 2025. "We are excited to share this pivotal milestone in VERAXA's journey toward becoming a publi

    7/17/25 1:00:00 AM ET
    $VACH

    VERAXA Biotech to Attend Key Industry Conferences to Showcase BiTAC Technology Platform

    ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today it will be attending the upcoming ASCO Annual Meeting and BIO International Convention. At the conferences, Christoph Antz, CEO, and additional members of the VERAXA leadership team will be meeting with potential partners and investors, showcasing the Company's novel Bi-targeted Tumor-Associated Cytotoxicity (BiTAC) platform, and sharing the Company's growth plans as it prepares to list on the NASDAQ later this year. VERAXA is leveraging its proprietary BiTAC p

    5/29/25 10:34:13 AM ET
    $VACH

    VERAXA Biotech Appoints Rick Austin as Chief Scientific Officer

    VERAXA Biotech AG ("VERAXA"), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, "Voyager")), announced today the appointment of Rick Austin, Ph.D. as Chief Scientific Officer, effective May 1st. Dr. Austin brings more than 25 years of leadership across oncology discovery and early development and will play a key role In advancing VERAXA's BiTACTM platform and clinical-stage pipeline. "Dr. Austin's appointment comes at a transformative period for VERAXA and I'm looking forward to working with him as we enter the next phase in VERAXA's journey," commented Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA

    5/20/25 1:00:00 AM ET
    $VACH

    $VACH
    SEC Filings

    View All

    SEC Form 10-Q filed by Voyager Acquisition Corp

    10-Q - Voyager Acquisition Corp./Cayman Islands (0002006815) (Filer)

    8/14/25 4:05:44 PM ET
    $VACH

    Amendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition Corp

    SCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

    8/14/25 1:56:08 PM ET
    $VACH

    Amendment: SEC Form SCHEDULE 13G/A filed by Voyager Acquisition Corp

    SCHEDULE 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

    8/8/25 9:50:01 AM ET
    $VACH

    $VACH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Voyager Acquisition Corp

    SC 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

    11/14/24 5:32:56 PM ET
    $VACH

    SEC Form SC 13G filed by Voyager Acquisition Corp

    SC 13G - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

    11/14/24 1:17:46 PM ET
    $VACH

    Amendment: SEC Form SC 13G/A filed by Voyager Acquisition Corp

    SC 13G/A - Voyager Acquisition Corp./Cayman Islands (0002006815) (Subject)

    11/6/24 3:00:45 PM ET
    $VACH